Compare Regeneron Pharmaceuticals Inc (REGN) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs SYSCO Corporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while SYSCO Corporation trades at $81.47 (market cap $38.84B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and SYSCO Corporation pays the higher dividend (2.71%). Which is the better fit depends on your goals.
| REGN | SYY | |
|---|---|---|
Market Cap | $70.79B | $38.84B |
Sector | Health | Consumer Staples |
52-Week High | $812.27 | $91.16 |
52-Week Low | $545.46 | $69.30 |
Enterprise Value | $64.74B | $52.32B |
Dividend Yield | 0.56% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SYY trades at $81.22, down 0.58% on the day, with a bullish technical signal supported by moving averages. The company reported mixed Q1 2026 earnings, missing EPS expectations of $0.945 with $0.94, but maintains strong revenue growth, reaching $81.37B in 2025. Analyst consensus is bullish with a $84.75 price target, and the upcoming Q4 2026 earnings report on August 4 is a key catalyst. Recent news highlights operational efficiency gains and AI integration, including a Newsweek AI Impact Award.
SYY presents a moderate buy opportunity with upside to the consensus target, supported by stable cash flow and dividend payments. Risks include thin net margins of 2.08% and elevated debt levels, with long-term debt at $11.51B. The stock's valuation is reasonable with a P/E of 22.44, but margin pressure and economic sensitivity in the food distribution sector warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
